E Maseroli1, E Fanni1, M Fambrini2, B Ragghianti3, E Limoncin4, E Mannucci3, M Maggi1, L Vignozzi5. 1. Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences "Mario Serio", University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. 2. Gynecology and Obstetrics Unit, Department of Experimental, Clinical and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. 3. Diabetes Agency, Careggi Hospital, Florence, Italy. 4. School of Sexology, Department of Clinical, Applied and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy. 5. Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences "Mario Serio", University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. l.vignozzi@dfc.unifi.it.
Abstract
PURPOSE: Female Sexual Dysfunction (FSD) is a still poorly studied and underdiagnosed condition. The aim of the study was to produce an improved version of FSFI-6 (6-Item Version of the Female Sexual Function Index), entitled Female Sexual Dysfunction Index-6 (FSDI-6), and to estimate its accuracy as a screening instrument for FSD. METHODS: In the new version, an item related to the personal interest in having a satisfying sex life was added, while the item rating the entity of sexual arousal was removed. We administered FSDI-6 in a consecutive series of female adult patients not consulting for sexual problems (n = 120, Cohort 1), and in another series of patients specifically consulting for sexual problems, which were considered as the control group (n = 160, Cohort 2). RESULTS: FSDI-6 score was significantly higher in patients in Cohort 2 (p < 0.0001). Cronbach's alpha for FSDI-6 was 0.784, indicating a high level of reliability. The estimated area under the ROC curve for FSDI-6 was 0.657 (p < 0.0001, 95 % CI 0.584-0.730). The proportion of subjects with a pathological FSDI-6 score (≥16.5) was 29.9 (n = 32) and 59.4 % (n = 95) in Cohort 1 and 2, respectively (p < 0.0001). Among subjects with a pathological FSDI-6 (score ≥16.5), those consulting for FSD had been postmenopausal for fewer years, had a higher level of education, a lower BMI and a lower prevalence of chronic diseases than those not consulting for FSD (p < 0.05). CONCLUSIONS: Although a lower educational level, overweight/obesity, menopause and chronic diseases are risk factors for FSD, they are often associated with the failure in medical consultation for FSD. We propose that FSDI-6 should be performed by health care providers in non-specialist settings to detect potential FSD, which otherwise could remain under-diagnosed.
PURPOSE: Female Sexual Dysfunction (FSD) is a still poorly studied and underdiagnosed condition. The aim of the study was to produce an improved version of FSFI-6 (6-Item Version of the Female Sexual Function Index), entitled Female Sexual Dysfunction Index-6 (FSDI-6), and to estimate its accuracy as a screening instrument for FSD. METHODS: In the new version, an item related to the personal interest in having a satisfying sex life was added, while the item rating the entity of sexual arousal was removed. We administered FSDI-6 in a consecutive series of female adult patients not consulting for sexual problems (n = 120, Cohort 1), and in another series of patients specifically consulting for sexual problems, which were considered as the control group (n = 160, Cohort 2). RESULTS:FSDI-6 score was significantly higher in patients in Cohort 2 (p < 0.0001). Cronbach's alpha for FSDI-6 was 0.784, indicating a high level of reliability. The estimated area under the ROC curve for FSDI-6 was 0.657 (p < 0.0001, 95 % CI 0.584-0.730). The proportion of subjects with a pathological FSDI-6 score (≥16.5) was 29.9 (n = 32) and 59.4 % (n = 95) in Cohort 1 and 2, respectively (p < 0.0001). Among subjects with a pathological FSDI-6 (score ≥16.5), those consulting for FSD had been postmenopausal for fewer years, had a higher level of education, a lower BMI and a lower prevalence of chronic diseases than those not consulting for FSD (p < 0.05). CONCLUSIONS: Although a lower educational level, overweight/obesity, menopause and chronic diseases are risk factors for FSD, they are often associated with the failure in medical consultation for FSD. We propose that FSDI-6 should be performed by health care providers in non-specialist settings to detect potential FSD, which otherwise could remain under-diagnosed.
Entities:
Keywords:
Female sexual dysfunction; Questionnaire; Referral; Screening
Authors: Jan L Shifren; Brigitta U Monz; Patricia A Russo; Anthony Segreti; Catherine B Johannes Journal: Obstet Gynecol Date: 2008-11 Impact factor: 7.661
Authors: Andrea M Isidori; Carlotta Pozza; Katherine Esposito; Dario Giugliano; Susanna Morano; Linda Vignozzi; Giovanni Corona; Andrea Lenzi; Emmanuele A Jannini Journal: J Sex Med Date: 2009-12-01 Impact factor: 3.802
Authors: A La Torre; G Giupponi; D M Duffy; M Pompili; M Grözinger; H P Kapfhammer; A Conca Journal: Pharmacopsychiatry Date: 2013-11-12 Impact factor: 5.788
Authors: M I Maiorino; G Bellastella; F Castaldo; M Petrizzo; D Giugliano; K Esposito Journal: J Endocrinol Invest Date: 2016-09-09 Impact factor: 4.256
Authors: Daniele Mollaioli; Stefania Di Sante; Erika Limoncin; Giacomo Ciocca; Giovanni Luca Gravina; Elisa Maseroli; Egidia Fanni; Linda Vignozzi; Mario Maggi; Andrea Lenzi; Emmanuele A Jannini Journal: PLoS One Date: 2018-08-29 Impact factor: 3.240